BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17525897)

  • 21. Acute spontaneous tumor lysis syndrome in a patient with Crohn's disease taking immunosuppressants.
    Froilán Torres C; Castro Carbajo P; Pajares Villarroya R; Plaza Santos R; Gómez Senent S; Martín Arranz MD; Adán Merino L; Martín Arranz E; Manceñido Marcos N; Peces R; Benito López D
    Rev Esp Enferm Dig; 2009 Apr; 101(4):288-94. PubMed ID: 19492906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New insights into renal transport of urate.
    Anzai N; Kanai Y; Endou H
    Curr Opin Rheumatol; 2007 Mar; 19(2):151-7. PubMed ID: 17278930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tumor lysis syndrome].
    Mieczkowski M; Matuszkiewicz-Rowińska J; Kościelska M
    Wiad Lek; 2015; 68(4 Pt 2):664-7. PubMed ID: 27162307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal-induced arthropathies: recent investigative advances.
    Ellman MH; Becker MA
    Curr Opin Rheumatol; 2006 May; 18(3):249-55. PubMed ID: 16582687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consensus conference on the management of tumor lysis syndrome.
    Tosi P; Barosi G; Lazzaro C; Liso V; Marchetti M; Morra E; Pession A; Rosti G; Santoro A; Zinzani PL; Tura S
    Haematologica; 2008 Dec; 93(12):1877-85. PubMed ID: 18838473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of tumor lysis syndrome in an outpatient setting.
    Mackiewicz T
    Clin J Oncol Nurs; 2012 Apr; 16(2):189-93. PubMed ID: 22459528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour lysis syndrome: an unusual presentation.
    Chubb EA; Maloney D; Farley-Hills E
    Anaesthesia; 2010 Oct; 65(10):1031-3. PubMed ID: 20645952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
    Cheson BD
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):263-71. PubMed ID: 19521331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in non-diabetic patients with stage 2-4 chronic kidney disease.
    Malyszko J; Bachorzewska-Gajewska H; Sitniewska E; Malyszko JS; Poniatowski B; Dobrzycki S
    Ren Fail; 2008; 30(6):625-8. PubMed ID: 18661413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor lysis syndrome: pathogenesis and management.
    Jones DP; Mahmoud H; Chesney RW
    Pediatr Nephrol; 1995 Apr; 9(2):206-12. PubMed ID: 7794722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current understanding of tumor lysis syndrome.
    Rahmani B; Patel S; Seyam O; Gandhi J; Reid I; Smith N; Khan SA
    Hematol Oncol; 2019 Dec; 37(5):537-547. PubMed ID: 31461568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma.
    Nakamura Y; Nakamura Y; Hori E; Furuta J; Ishii Y; Takahashi T; Kawachi Y; Otsuka F
    Int J Dermatol; 2009 Jul; 48(7):763-7. PubMed ID: 19570088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hereditary renal hypouricemia.
    Sperling O
    Mol Genet Metab; 2006; 89(1-2):14-8. PubMed ID: 16678460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor lysis syndrome.
    Akers PA
    Dimens Oncol Nurs; 1990; 4(4):10-3. PubMed ID: 2132919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor lysis syndrome.
    Arrambide K; Toto RD
    Semin Nephrol; 1993 May; 13(3):273-80. PubMed ID: 8321927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome.
    May HP; Mara KC; Barreto EF; Leung N; Habermann TM
    Leuk Lymphoma; 2021 Dec; 62(13):3152-3159. PubMed ID: 34169786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How we treat tumor lysis syndrome.
    Muslimani A; Chisti MM; Wills S; Nadeau L; Zakalik D; Daw H; Huang J; Jaiyesimi I
    Oncology (Williston Park); 2011 Apr; 25(4):369-75. PubMed ID: 21618960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
    Dalbeth N; Stamp L
    Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cystatin C in acute heart failure without advanced renal impairment.
    Naruse H; Ishii J; Kawai T; Hattori K; Ishikawa M; Okumura M; Kan S; Nakano T; Matsui S; Nomura M; Hishida H; Ozaki Y
    Am J Med; 2009 Jun; 122(6):566-73. PubMed ID: 19393984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Refractory gout: what is it and what to do about it?
    Fels E; Sundy JS
    Curr Opin Rheumatol; 2008 Mar; 20(2):198-202. PubMed ID: 18349751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.